^
Association details:
| Biomarker: | AXL overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AXL inhibition improves BRAF-targeted treatment in melanoma
Published date:
03/24/2022
Excerpt:
To evaluate the effect of the combination treatment in vivo, Melmet 1 xenografts were established and treated with AXLi, BRAFi or a combination of both, twice daily for 14 days (Fig. 6a)....Compared to either one of the mono-treatments, a significant regression in tumor size was observed when xenografts were treated with the AXLi and BRAFi combination.
DOI:
10.1038/s41598-022-09078-z
